Top Research Papers on Statistics

The research progress of bone destruction participated by JAK / STAT in rheumatoid arthritis and therapeutic effect of JAK/STAT inhibitors were reviewed.

This Review highlights the central roles of signal transducer and activator of transcription (STAT) proteins, notably STAT3, STAT5, STAT6 and STAT1, in orchestrating the highly dynamic metabolism not only of cancer cells but also of immune cells and adipocytes in the tumour microenvironment.

To enhance STAT1 activity and/or inhibit STAT3 functions for COVID-19 treatment is suggested, which might derail the escalating STAT3/PAI-1 cycle central to CO VID-19.

It is posit that dysregulated Janus kinase/signal transducer and activator of transcription (JAK/STAT) signaling represents one major hub of tumorigenesis and resistance to medical therapies and that clinical study of its targeted inhibition is warranted, as well as highlighting the lessons learned from historical investigation going forward.

In this review, the current knowledge about the composition, activation, and regulation of the JAK/STAT pathway is discussed and the role of this signaling pathway and its inhibitors in various diseases is highlighted.

It is suggested that Jak1 and Jak2 inhibition may relieve pain in RA caused by inflammatory and non-inflammatory mechanisms and are consistent with the overarching involvement of the Jak-signal transducer and activator of transcription (Jak/STAT) pathway in mediating the action, expression, and regulation of a multitude of pro- and anti-inflammatory cytokines.

Inflammation being a significant influencer in COVID-19 patients, it drives the focus onto the signaling cascades of the JAK/STAT pathway, which produces various inflammatory markers in the host that determine the disease severity.

The JAK/STAT signaling pathway is an universally expressed intracellular signal transduction pathway and involved in many crucial biological processes, including cell proliferation, differentiation, apoptosis, and immune regulation, which provides a direct mechanism for extracellular factors-regulated gene expression.

New approaches such as selective or gut-specific JAK inhibitors, and a greater understanding of disease-specific mechanisms of action to facilitate personalized approaches to treatment, could improve the risk–benefit profiles of this class of therapy.

The JAK/STAT signaling pathways of various cytokines involved in AA are highlighted and how targeting those pathways may impact disease outcomes in both laboratory and clinical settings is highlighted.

An overview of SARS-CoV-2 and COVID-19 is presented, and the potential efficacy and interactions of these potential targets which are directly affected by the ruxolitinib or JAK/STAT pathway are evaluated.

Findings revealed mechanisms underlying rapid gene expression mediated by a wide variety of extracellular polypeptides including cytokines, interleukins, and related factors, and provided numerous insights into human disease.

The role of Jak–STAT pathways in the pathogenesis of AD is reviewed and updated applications of JAK inhibitors in treating AD are explored.

The role of the JAK/STAT pathway in mechanistic signaling, disease progression, immune environment, and therapeutic targets is discussed.

It is found that plasticity initiates in an epithelial population defined by mixed luminal-basal phenotype and that it depends on increased Janus kinase (JAK) and fibroblast growth factor receptor (FGFR) activity.

The current understanding of the fundamental composition and function of the JAK-STAT signaling pathway is reviewed and advancements in the understanding of Jak-STAT–related pathogenic mechanisms are discussed.

Evidence indicates that JAK inhibitors or monoclonal antibodies directed to block IL-6 are used as compassionate use to attenuate the excessive inflammation and lung fibrosis related to SARS-CoV-2 virus, and JAK/STAT pathway is an attractive target to be proven in future clinical trials of lung fibrotic disorders.

The roles and mechanisms of the JAK/STAT signaling pathway in fibrotic diseases are reviewed, which are closely related to growth and development, homeostasis, various solid tumors, inflammatory illness, and autoimmune diseases.

This review provides a revised framework for understanding the diverse kaleidoscope of STAT protein functional modalities and discusses the implications of this framework for the understanding of STAT proteins in normal blood and immune cell biology and diseases such as cancer.

The diverse roles that each STAT family member plays in breast cancer pathobiology are summarized, as well as, the opportunities and challenges in pharmacologically targeting STAT proteins and their upstream activators in the context of breast cancer treatment.